Figure 6
Figure 6. UPR induction in P2 BLCL. (A) Immunoblot showing the expression level of GRp78 and GRp94 in control (C) and patient's BLCLs. HEK-293 cells, untreated (-) or treated for 6 hours with 2 different doses of Tunicamycin (TM) are shown as control of UPR induction. Tubulin was used as loading control. (B) Real-time PCR analysis of GRp78 and ERdJ4 mRNA expression, in C and mutant BLCLs, untreated or treated with TM. Expression values, relative to β-actin, are normalized to the expression observed in C. The experiment shown is representative of 2 independent experiments with triplicate samples, and data are given as means ± SD. (C) RT-PCR analysis of XBP1 mRNA, spliced (sXBP1) and unspliced (uXBP1). The experiment shown is representative of 2 independent experiments. Vertical lines have been inserted to indicate repositioned gel lanes.

UPR induction in P2 BLCL. (A) Immunoblot showing the expression level of GRp78 and GRp94 in control (C) and patient's BLCLs. HEK-293 cells, untreated (-) or treated for 6 hours with 2 different doses of Tunicamycin (TM) are shown as control of UPR induction. Tubulin was used as loading control. (B) Real-time PCR analysis of GRp78 and ERdJ4 mRNA expression, in C and mutant BLCLs, untreated or treated with TM. Expression values, relative to β-actin, are normalized to the expression observed in C. The experiment shown is representative of 2 independent experiments with triplicate samples, and data are given as means ± SD. (C) RT-PCR analysis of XBP1 mRNA, spliced (sXBP1) and unspliced (uXBP1). The experiment shown is representative of 2 independent experiments. Vertical lines have been inserted to indicate repositioned gel lanes.

Close Modal

or Create an Account

Close Modal
Close Modal